ADAG Financials: Adagene Inc AI Analysis

Home

Stock

ADAG

Financials

ADAG Financial

Adagene Inc

$3.61

-7.9%

$-0.31

At close: Mar 24, 16:00:00 GMT-4

$3.61

Post-market: Mar 24, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$3.92

Open

$3.87

Day's Range

$3.44 - $3.89

52 week range

$1.3 - $4.57

Volume

67.1K

Avg.Volume

177.5K

Dividend yield

EPS (TTM)

-0.51

Market Cap

$170.0M

What is ADAG?

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 138 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

ADAG Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	0	18	9	10	0
Revenue Growth (YoY)	--	-100%	100%	-10%	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	7	7	8	11	14	10
Research & Development	26	28	36	81	68	33
Operating Expenses	33	36	41	93	82	43
Other Non Operating Income (Expenses)	0	0	1	2	1	0
Pretax Income	-29	-33	-17	-79	-71	-42
Income Tax Expense	0	0	1	0	1	0
Net Income	-29	-33	-18	-79	-73	-42
Net Income Growth	-6%	83%	-77%	8%	74%	163%
Shares Outstanding (Diluted)	58.89	56.28	54.73	54.14	50.03	43.85
Shares Change (YoY)	7%	3%	1%	8%	14%	-17%
EPS (Diluted)	-0.51	-0.59	-0.34	-1.48	-1.46	-0.97
EPS Growth	-11%	72%	-77%	1%	51%	202.99%
Free Cash Flow	-27	-29	-28	-49	-45	-29
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	-127.77%	-922.22%	-720%	0%
Profit Margin	0%	0%	-100%	-877.77%	-730%	0%
Free Cash Flow Margin	0%	0%	-155.55%	-544.44%	-450%	0%
EBITDA	-33	-35	-23	-82	-71	-43
EBITDA Margin	0%	0%	-127.77%	-911.11%	-710%	0%
D&A For EBITDA	0	0	0	1	1	0
EBIT	-33	-35	-23	-83	-72	-43
EBIT Margin	0%	0%	-127.77%	-922.22%	-720%	0%
Effective Tax Rate	0%	0%	-5.88%	0%	-1.4%	0%

Follow-Up Questions

What are Adagene Inc's key financial statements?



According to the latest financial statement (Form-10K), Adagene Inc has a total asset of $89, Net loss of $-33

What are the key financial ratios for ADAG?



Adagene Inc's Current ratio is 2.34, has a Net margin is 0, sales per share of $0.

How is Adagene Inc's revenue broken down by segment or geography?



Adagene Inc largest revenue segment is Monoclonal Antibody Drugs, at a revenue of 103,204 in the most earnings release.For geography, China is the primary market for Adagene Inc, at a revenue of 103,204.

Is Adagene Inc profitable?



no, according to the latest financial statements, Adagene Inc has a net loss of $-33

Does Adagene Inc have any liabilities?



yes, Adagene Inc has liability of 38

How many outstanding shares for Adagene Inc?



Adagene Inc has a total outstanding shares of 58.88

Adagene Inc (ADAG) Financial

ADAG Stock Price Chart